Vimarsana
Biggest News Aggregation in the World

Page 7 - Latest Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Latest Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Latest Data Today - Breaking & Trending Today

At an impressive CAGR of 20.5%, the 3D Printing Market share is anticipated to be worth of about US$ 148.4 Bn by year 2032-end. Get latest data analysis by the experts at FMI - Vimarsana News

At an impressive CAGR of 20.5%, the 3D Printing Market share is anticipated to be worth of about US$ 148.4 Bn by year 2032-end. Get latest data analysis by the experts at FMI

At an impressive CAGR of 20.5%, the 3D Printing Market share is anticipated to be worth of about US$ 148.4 Bn by year 2032-end. Get latest data analysi

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting - Vimarsana News

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting - Vimarsana News

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...

Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition - Vimarsana News

Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition

/PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced preliminary clinical data for...

More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting - Vimarsana News

More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting

- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib